A recent comprehensive systematic review and meta-analysis has scrutinized the impact of cannabis use on non-medical opioid use among patients undergoing treatment for opioid use disorder (OUD), challenging the efficacy of cannabis in treating opioid addiction while also questioning the requirement for cannabis abstinence in opioid treatment programs.
The study, meticulously fact-checked and trusted per Science X’s editorial process, casts a significant light on a critical area of addiction medicine. With over 120 people dying daily from drug overdoses involving opioids and an economic burden exceeding $1 trillion a year in the United States, the urgency to optimize OUD treatment is palpable.
Cannabis Approval for Opioid Use Disorder Treatment
Currently, widespread legalization and reduced perceived harm of cannabis have prompted some U.S. states to list OUD as an approved condition for medical cannabis. Proponents of this legislature were buoyed by previous evidence suggesting that cannabis might mitigate opioid withdrawal and pain, a cornerstone symptom leading to opioid relapse. Observational studies hinted at the possibility of cannabis use decreasing the rate of non-medical opioid use through its ‘opioid-sparing’ effects.
However, Gabriel Costa, under the mentorship of Dr. Joao P. De Aquino and colleagues, interrogated this stance by reviewing ten longitudinal studies involving 367 individuals receiving pharmacotherapies, such as methadone, buprenorphine, or naltrexone, for OUD. Contrary to the advocacy for medical cannabis as a harm reduction strategy and contrary to concerns that cannabis might exacerbate opioid addiction, the study’s findings revealed no significant association between cannabis and non-medical opioid use. Costa elucidates,
Overall, we found no significant association between cannabis and non-medical opioid use among patients receiving pharmacotherapies for opioid use disorder.
These results neither vilify nor vindicate cannabis use during MOUD, suggesting instead that individualized treatment approaches should be adopted.
Cannabis Abstinence Unnecessary for Opioid Addiction Treatment
Dr. De Aquino shared corresponding sentiments, underlining the inefficacy of enforcing cannabis abstinence as a life-saving treatment prerequisite and emphasizing the lifesaving nature of FDA-approved treatments. “Methadone, buprenorphine, and extended-release intramuscular naltrexone—are known to be life-saving and are the cornerstone of opioid use disorder management,” he asserts.
The study highlights the necessity for randomized placebo-controlled trials to overcome the limitations of observational studies, which may not adequately demonstrate causality. Trial researchers recommend adopting standardized measures across studies, including specific assessments of cannabis and opioid use patterns, to enable reliable comparisons.
The rigorous review, set to be published in The American Journal of Drug and Alcohol Abuse, points to a nuanced relationship between cannabis and opioid addiction treatment. While the association between the two remains inconclusively linked, the findings advise against categorical cannabis abstinence mandates for OUD treatment and support individualized, evidence-based approaches considering each patient’s unique needs and circumstances.
No One-Size-Fits-All Treatment for Opioid Use Disorder
The comprehensive scope of the study and its implications extend beyond OUD treatment, touching upon broad concerns of medical cannabis laws, the shifting landscape of cannabis legalization, and the need for reassessment of current policies based on emerging scientific analyses. As the scientific community continues to delve into the role of cannabis in the complex domain of addiction medicine, it is becoming increasingly clear that a one-size-fits-all mandate is an ineffective approach, and a nuanced, patient-focused treatment paradigm is essential for advancing the management of opioid use disorder, pain, and related public health challenges.
The call for more experimental studies on cannabis and OUD intersects with the ever-present quest for evidence in addiction treatment, underscoring the critical importance of broadening our scientific understanding to improve healthcare outcomes in the face of the opioid epidemic. As high-potency synthetic opioids like fentanyl become more available, ensuring that individuals with opioid use disorder have access to effective treatments becomes all the more imperative, thus saving lives and reducing the colossal economic impact of opioid addiction.
